Ajinomoto Althea Adds High Potency Capabilities
PTSM: Pharmaceutical Technology Sourcing and Management
Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.
Ajinomoto Althea, Inc. announced on Sept. 19, 2017 that the company will open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA. The facility is designed to develop, manufacture, test, and release HPPs including antibody drug conjugates, highly potent APIs, and other complex formulations of highly potent drugs.
The company currently offers process development and analytical services to clients from the facility and will be open for GMP bioconjugation and complex formulation in November 2017. Full manufacturing services, including high containment fill and finish, will commence in Q4 2018, as reported in a press statement on Sept. 19, 2017.
The company also announced that it secured its first manufacturing contract for the new facility.
Source: Ajinomoto Althea
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
